Adverse drug reactions have been linked with genetic polymorphisms in HLA genes in numerous 8 different studies. HLA proteins have an essential role in the presentation of self and non-self peptides, 9
as part of the adaptive immune response. Amongst the associated drugs-allele combinations, anti-HIV 1 0 drug Abacavir has been shown to be associated with the HLA-B*57:01 allele, and anti-epilepsy drug 1 1
Carbamazepine with B*15:02, in both cases likely following the altered peptide repertoire model of 1 2
interaction. Under this model, the drug binds directly to the antigen presentation region, causing 1 3 different self peptides to be presented, which trigger an unwanted immune response. There is growing 1 4 interest in searching for evidence supporting this model for other ADRs using bioinformatics 1 5 techniques. In this study, in silico docking was used to assess the utility and reliability of well-known 1 6 docking programs when addressing these challenging HLA-drug situations. Four docking programs: 1 7
SwissDock, ROSIE, AutoDock Vina and AutoDockFR, were used to investigate if each software 1 8 could accurately dock the Abacavir back into the crystal structure for the protein arising from the 1 9 known risk allele, and if they were able to distinguish between the HLA-associated and non-HLA-2 0 associated (control) alleles. The impact of using homology models on the docking performance and 2 1
The SwissDock [31] server is an online tool based on the EADock DSS [32] engine. Target and 1 1 1 ligand structures can be automatically prepared for docking through the server. Target structures can 1 1 2 be selected via PDB records, or user-defined structures can be uploaded in various supported formats. 1 1 3
Ligands can be selected through the ZINC database or by uploading structure files. A range of 1 1 4 docking parameters can be set, including docking type, enabling the user to select a desired docking 1 1 5 time and exhaustiveness, and defining the search space [31] . Due to it being an online tool, it is very 1 1 6 accessible and can be used without the technical knowledge required for some of the more complex 1 1 7
software. 1 1 8
The Rosetta Online Server that Includes Everyone (ROSIE) is an online version of the Rosetta 3 1 1 9 software. The server includes different Rosetta protocols, including RosettaLigand which allows small 1 2 0 molecules to be docked into proteins. The target structure must be provided in PDB format. For best 1 2 1 results, residues that Rosetta does not natively recognise (e.g. waters, co-factors or metal ions) should 1 2 2 be removed prior to submission. An SDF file containing the conformers of a single ligand should also 1 2 3 be provided. The approximate location of the binding site should also be specified, as RosettaLigand 1 2 4 cannot perform binding site detection. Again, multiple parameters can be selected [33, 34] . 1 2 5
Finally, two versions of AutoDock were also used, both tools that can be installed and run locally. 1 2 6
AutoDock Vina was shown to be a strong competitor against six other programs when tested against a 1 2 7 virtual screening benchmark [35] . The latest AutoDock software, AutoDockFR was also used. 1 2 8
AutoDockFR uses a genetic algorithm and scoring function based on the AutoDock4 scoring function. 1 2 9
This program differs from the others as it takes into account receptor flexibility by allowing the user 1 3 0 to specify flexible residues within the target structure, this allows the program to simulate induced fit 1 3 1 caused by ligand binding where changes occur mainly in the residues side chains. This software was 1 3 2 shown to outperform AutoDock Vina for tested datasets [36] . For both of the AutoDock versions, 1 3 3 target and ligand structures are to be provided in PDBQT format. The search space, including the 1 3 4 binding site, must also be specified with other optional parameters also available. AutoDock is 1 3 5 commonly used for in-silico docking of associated drugs with HLA alleles. It is therefore important to 1 3 6 assess the reliability of the different versions of this program when using the complex HLA structure Two drugs were investigated. Abacavir, an anti-retroviral drug used to supress HIV replication, is the 1 3 9 most widely investigated drug associating ADRs with HLA. It has been shown that there is a genetic 1 4 0 association between HLA-B*57:01 and Abacavir [4, 37, 38] . The ADR is thought to be driven by the 1 4 1 activation of CD8+ T cells [39] . The mechanism of Abacavir binding has been experimentally 1 4 2 validated by X-ray crystallography and shown to correspond with the altered peptide repertoire 1 4 3 model. Abacavir binds directly and non-covalently with the HLA-B*57:01 binding cleft in the F-1 4 4 pocket (Fig 1) of the peptide-binding groove [40] . This binding results in an alteration of the 1 4 5 physicochemical parameters and topography of the binding groove, altering the presented peptides 1 4 6 and eliciting a polyclonal T-cell response leading to the Abacavir hypersensitivity reaction. 1 4 7
Alterations at key residues within the binding cleft have been shown to prevent the Abacavir 1 4 8 therefore be used to test if the docking methods used predict the same binding position shown in these 1 6 7 previous independent studies. 1 6 8
In this work, we used the Abacavir example for which a crystal structure of the complex exists, as a 1 6 9 benchmark for the docking software. By using molecular docking, the binding position of the 1 7 0
Abacavir within the B*57:01 risk allele HLA structure and, for comparison, with the non-risk control 1 7 1 allele structures was predicted. Controls were chosen from B alleles shown to be non-risk (B*57:03) 1 7 2 and common HLA-B and HLA-A alleles (B*07:02 and A*01:01). We work under the assumption that 1 7 3 for (control) alleles that have not been associated with an ADR, that this is due to drug not binding 1 7 4 sufficiently strongly to affect peptide presentation. Illing et al. showed that Abacavir interacts non-1 7 5 covalently with the B*57:01 risk allele but not with B*57:03 control [8] . The docking results were 1 7 6 then compared to the known binding position to estimate the reliability of the docking protocol. In 1 7 7 addition, we assessed to what extent the docking could distinguish between the HLA-associated and 1 7 8 non-HLA-associated alleles. The same methods were used to test if the Carbamazepine binding 1 7 9 position previously seen can be reliably replicated, using the programs showing the most accurate 1 8 0 results for the Abacavir example. Due to there being more evidence available for the Abacavir 1 8 1 example, including a crystal structure of the drug bound in complex, our investigations favour this 1 8 2 example. For the Carbamazepine example, we are comparing our results against a previous prediction 1 8 3 using similar methods. 1 8 4
This work sheds light on the utility and reliability of well-known docking programs used to address 1 8 5 the challenging HLA-drug situation. These docking methods may help us to understand the 1 8 6 mechanisms behind ADRs and identify genetic polymorphisms that may be influencing the binding 1 8 7 seen in the risk but not control alleles. For the Abacavir example, B*57:01 has been shown to be a risk allele and B*57:03 not associated. 1 9 1
For Carbamazepine B*15:02 was found to be the risk allele, with B*15:01 not being associated. These 1 9 2 non-associated alleles were therefore used as controls along with a common HLA-B allele (B*07:02) 1 9 3 and HLA-A allele (A*01:01) which could be assumed to not be associated as they are seen at a high 1 9 4 frequency across European origin (Caucasian) populations (average frequencies obtained from AFND 1 9 5 using gold standard populations [9]: B*57:01 = 0.03, B*07:02=0.10 and A*01:01=0.14). 1 9 6
The allele structures were obtained from the PDB database, where available. Models were made for 1 9 7 those alleles where the structure is not publicly available (Table 1) . Target and template sequences 1 9 8
were aligned with ClustalX [42] . For each modelling exercise, ten models were generated using 1 9 9
Modeller 9.9 automodel class and the model with the lowest objective function score was chosen as 2 0 0 the model for docking. This objective function is a score generated from the spatial restraints and the 2 0 1 CHARMM energy terms, reflecting stereochemistry within the structure [43] .In these simple cases 2 0 2 there was no need to explore alternative target-template alignments since sequences could be aligned 2 0 3 unambiguously with no insertions or deletions. The Abacavir risk and control alleles were used to evaluate the homology modelling as the known 2 0 9 structures are available for each allele investigated and so can be compared with the model structure 2 1 0 and docking results. Two models were created for B*57:03, one with one template allele (B5703_m) 2 1 1 and another with two template alleles (B5703_m2). These models could then be compared to the 2 1 2 known structure of B*57:03 (B5703_s), as could the docking predictions, to understand the influence 2 1 3 of these steps when employed in a typical docking protocol. The structure of B*57:01 was also 2 1 4 modelled (B5701_m), from two similar sequences identified to make similar comparisons and 2 1 5 evaluate the reliability of using homology modelling. 2 1 6
For the Carbamazepine risk associated allele B*15:02, there are four differing residues with control 2 1 7 allele B*15:01. Three of these lie in the peptide binding groove, with only one of these being vital to 2 1 8 the D-pocket architecture, where the Carbamazepine is predicted to bind (pos 156). Only a single 2 1 9 template, the structure of B*15:01, was therefore used to model B*15:02 (B1502_m). 2 2 0
The quality of each model was investigated using Ramachandran plots and QMEAN scores. For the 2 2 1
B5701_m and B5703_ m and m2, RMSDs were used to give a measure of how well the models 2 2 2 represent the known structures. The percentage sequence identity for each of the templates used for 2 2 3 each model are shown in S1 Table. 2 2 4 2.1.1. Conformational sampling of receptor protein structures 2 2 5
In order to identify the flexible side chains for the target structure, the relax function of Rosetta was 2 2 6 used to explore the conformational properties of each residue. By looking at 10 different relaxed 2 2 7 structures for each target, flexible residues can be identified. This allows us to consider the flexibility 2 2 8 of the target structure when using AutoDockFR. When using the ROSIE server, a similar sampling is 2 2 9 incorporated into the docking procedures [34] . Using SwissDock [31], the default parameters search the whole target structure but by setting the 2 3 3 search space parameters, it is possible to restrict binding to perform a local docking assay using the 2 3 4 known binding pocket. Here, the area of interest is the peptide binding groove, including residues 1-2 3 5 180 of the alpha chain. The search space was therefore restricted to this area of interest. The file was 2 3 6 processed to ensure it was in the correct format to be uploaded to SwissDock. This included removing 2 3 7 the ligand and peptide from the structure. The PDB was then passed through the Prepdock server [50] 2 3 8 to prepare the structure for docking. This prepared file was then submitted to SwissDock with the 2 3 9 relevant known drug structures. SwissDock used the ZINC database to obtain the known structures of 2 4 0 compounds (Abacavir ZINC ID: 2015928, Carbamazepine ZINC ID: 4785). [33, 34] , was also used in a similar way. The PDB files were again prepared, removing the 2 4 3
ROSIE
Abacavir and peptide from 3VRI and this time also removing the water molecules from the target 2 4 4 structure, as Rosetta is unable to natively recognise these residues. The Abacavir drug structure was 2 4 5 extracted from the relevant PDB (3VRI) and converted to SDF format. This was then submitted to the 2 4 6 server to be docked, with the search space specified to centre on the peptide binding groove. This 2 4 7 process was repeated for each of the risk and control alleles to be investigated. Carbamazepine, there is no crystal structure available for the drug bound to a target and so the PDB 2 5 3 file was obtained from the ZINC entry previously used for the SwissDock docking and from the 2 5 4 Drugbank structure. 2 5 5
Using AutoDock Vina, a search space of 40x40x40Å was used. Initially, the default exhaustiveness 2 5 6 was used but this was then increased gradually to identify the best parameters to find the closest 2 5 7 docking poses of Abacavir to the native position seen in the crystal structure. Once this was identified, 2 5 8 the process was then repeated for the other alleles, using the same parameters. model to show a similar conformation to that seen in these known structures. This was not seen in the 3 0 7
B5703_m model but was seen in the B5703_m2 model in which two templates were used (S1 Fig) . Using two templates for the model gave a more accurate representation of this element of the target 3 0 9 structure in this case. 3 1 0 Using SwissDock, it can be seen that the B5701_s example gives a docking solution close to the 3 1 4 native position (Fig 2 a-c) with all poses showing binding in the F-pocket. When using AutoDockFR 3 1 5 assuming the receptor to be rigid, similar results were seen to those using SwissDock (Fig 2 d-f ). All 3 1 6 poses for the B5701_s risk allele were shown bound in the same pocket as the known binding 3 1 7 position. Little difference was seen between the docking shown for each search space, with only one 3 1 8 pose from the B*57:01 run showing binding outside of the peptide binding groove when the search 3 1 9 space was extended around the whole protein (data not shown). This indicates that the peptide binding 3 2 0 groove is the most favourable region for binding. It can be concluded overall that the Abacavir docks 3 2 1 in the expected binding pocket for these packages, but they cannot predict the exact native pose. As the ROSIE server allows movement of side chains within the target, the modelled structure of the 3 3 2 B*57:01 risk allele target was compared to the B5703_s structure submitted. This resulted in the 3 3 3 Table 2 with B5701_s giving similar average RMSDs to the control alleles. 3 3 4
Abacavir

RMSDs shown in
Comparing the lowest RMSDs, the control structures give poses with lower RMSDs than B5701_s. 3 3 5 For AutoDock Vina, exhaustiveness is shown in brackets as (exh=). The lowest and highest RMSDs are shown along with the averages for all poses, pose rank is shown in brackets. (For SwissDock, poses are ranked from 0-5. For ROSIE and AutoDock Vina, poses are ranked from 0-9. Rank is not shown for AutoDock FR, as each pose was taken from top pose for each of 10 runs). Search spaces include surrounding the peptide binding groove (PBG), surrounding around the known ligand binding position (Ligand) and
surrounding the top three largest binding pockets to increase the search space to enable binding away from the peptide binding groove (Top 3).
When docking the Abacavir structure using AutoDock Vina, the exhaustiveness was investigated 3 4 0 using the B*57:01 example (B5701_s) to optimise the protocol before docking the other non-risk 3 4 1 alleles. Using the default exhaustiveness of 8, the RMSD values were shown to be quite variable 3 4 2 (Table 2) . The exhaustiveness was then increased starting at exh=18 and doubling the exhaustiveness 3 4 3 to see the effect. It was found that the exhaustiveness of 112 gave the lowest RMSDs overall and 3 4 4 these did not improve with further increasing of exhaustiveness 3 4 5
Most docking software assessed can distinguish between risk and control alleles 3 4 6
Two methods were used to investigate if the docking software can distinguish between the risk alleles. 3 4 7 RMSD values, alongside some visual inspection, were used to give a measure of how similar the 3 4 8 docking prediction results are to the known binding position obtained from the crystal structure. 3 4 9
Docking scores were also investigated to see if there is more favourable binding seen in the risk 3 5 0 alleles compared to the controls and also how the scores differ between the predicted poses for the 3 5 1 risk allele itself. 3 5 2
Using RMSDs, it can be seen from Figure 3 and Table 2 that most of the software, excluding 3 5 3 "AutoDockFR (Ligand)" and ROSIE, showed lower RMSD's for B*57:01 than the other control 3 5 4 alleles investigated and were able to distinguish between the known risk allele structure (B5701_s) 3 5 5 It can be seen that B*57:01 generally had a lower average RMSD than the control alleles for all 3 8 3 software, excluding ROSIE, even with these reversed orientations discussed, with the lowest RMSD 3 8 4 being constantly lower than those seen for the controls. Both control alleles B*57:03 and B*07:02 3 8 5 contain a tyrosine at position 116, rather than the serine seen in the risk allele, with A*01:01 having 3 8 6 an aspartic acid at position 116. This residue is sensitive for the F-pocket architecture as it lies along 3 8 7 the base of the pocket [53] and so this mutation prevents binding in this native position. 3 8 8
The full fitness scores for SwissDock poses were investigated, with lower scoring poses being more 3 8 9 favourable than higher scoring poses. Scores were compared between B*57:01, B*57:03 and 3 9 0 B*07:02, it was found that poses for the B*57:01 risk allele scored more poorly than those for the 3 9 1 non-risk alleles (Fig 5a) , with the control alleles showing lower scores than the risk allele. This 3 9 2 implies that comparison of scores between alleles is not valid since better docking results were seen 3 9 3 for the risk allele. Put another way, the docking scores were not able to distinguish between the risk 3 9 4 and control alleles. Nevertheless, the scores for the B*57:01 risk allele are a good guide to pose 3 9 5 accuracy, as there is a modest positive correlation between RMSD and score (Fig 5b) , with an R 2 3 9 6 value of 0.65. binding position on Abacavir from 3VRI. This prevented the docking from predicting the exact native 4 0 5 pose. However, poses were still predicted within the F-pocket and had lower RMSDs seen than those 4 0 6 predicted for the non-risk alleles. This slight difference between the modelled and known structures 4 0 7 may be due to the peptide bound in the peptide binding groove of the 3VRI structure. 4 0 8
The docking of Abacavir to the known structure of the control allele B5703_s showed similar results 4 0 9
to the modelled structures, with poses seen away from the known Abacavir binding position and 4 1 0
higher RMSDs (S4 Fig). The average RMSDs seen with the B*57:03 known structure were higher 4 1 1 than those seen with the homology models, showing the Abacavir docks further from the known 4 1 2 binding position with the known structure. 4 1 3
Receptor flexibility negatively affects the docking performance 4 1 4
When the flexible residues were incorporated for the 3VRI docking with Abacavir example, poses 4 1 5 occupied the whole peptide binding groove and did not favour the F-pocket as expected ( Fig 6) . When 4 1 6 the scores for the poses found inside the F-pocket were compared to those found outside the F-pocket, 4 1 7
it was also seen that these scores did not favour the F-pocket (data not shown). Thus, although the 4 1 8 complex algorithms developed for AutoDockFR have been shown to improve the success of docking 4 1 9 the difficulties of using docking to investigate these challenging HLA-ADR cases as in general 4 4 7 docking for new ADRs will be performed, for example, on structures that have a peptide already 4 4 8 bound but not the drug that is to be docked. 4 4 9 3.3. Carbamazepine 4 5 0 SwissDock and AutoDockFR were best able to predict the binding positions of Abacavir and so these 4 5 1 programs were both used to predict the binding position of Carbamazepine with both the risk allele 4 5 2 (B1502_m) and the control alleles (B1501_s, A0101_s and B070_s2). The predicted poses were 4 5 3 compared to those shown in previous studies in which B*15:02 showed binding in the D-pocket, close 4 5 4 to residues 62, 63, 95 and 156 [8, 14] . 4 5 5
Docking Carbamazepine with B1502_m using SwissDock, the poses were predicted to sit in the D-4 5 6 pocket previously identified as of interest. Looking at the docking results (Fig 8a) , it can be seen that 4 5 7
Carbamazepine is predicted to bind in the D-pocket of B*15:02, close to Leu156, identified by the 4 5 8 study as important, with only one pose predicted out of this pocket. Using AutoDockFR, the same 4 5 9
general pattern was seen with the D-pocket generally being favoured for B*15:02 (Fig 8b) . Using 4 6 0 SwissDock, the B*15:01 docking showed poses predicted to bind elsewhere, away from this pocket, 4 6 1 as predicted. For the B*15:01, A*01:01 and B*07:02 alleles, with a mutation at this 156 position 4 6 2 (Leu→Trp, Leu→Arg and Leu→Arg respectively), this D-pocket is closed off and produces poses 4 6 3 elsewhere (S5 Fig). Using AutoDockFR, the same general pattern was seen with no poses being found 4 6 4 in or around the D-pocket for B*15:01. These predictions cannot be validated since there is, as of yet, 4 6 5 no crystal structure available for Carbamazepine bound to HLA. However, when compared to 4 6 6 previous studies, our results showed a similar binding position using different software. The purpose of this exercise was to compare multiple docking programs to assess their performance 4 7 2 with these challenging HLA-ADR cases. We used the Abacavir example as the benchmark for the 4 7 3
